Paper Details

  1. Home
  2. Paper Details

Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.

Author: BalnaveK, HarronD W, LeaheyW J, NeillJ D, RussellC J, ShanksR G, WilsonR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Betaxolol significantly reduced exercise tachycardia with a longer duration of action than other beta-blockers. It had a long plasma elimination half-life.
Paper Details　
Original Abstract of the Article :
1 Observations were made in five subjects who exercised before and at 2, 3, 6, 8, 24, 33 and 48 h after the oral administration of placebo and 5, 10, 20 and 40 mg betaxolol. 2 The exercise heart rate remained constant at all times after the placebo. All doses of betaxolol significantly reduced the e...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/j.1365-2125.1981.tb01121.x

データ提供：米国国立医学図書館（NLM）

Betaxolol: A Long-Lasting Beta-Adrenoceptor Antagonist

Betaxolol, a cardioselective beta-adrenoceptor blocking drug, has shown promise in treating various cardiovascular conditions. This research investigates the efficacy and pharmacokinetics of betaxolol in five subjects. The study aimed to assess the drug's effects on exercise tachycardia, its duration of action, and its plasma elimination half-life.

Betaxolol Demonstrates Potency and Longevity

The study found that betaxolol effectively reduced exercise tachycardia, demonstrating its potency as a beta-adrenoceptor antagonist. Furthermore, the drug exhibited a long duration of effect, lasting significantly longer than other beta-blockers. Betaxolol's long plasma elimination half-life indicates that it remains effective for a prolonged period, suggesting its potential for once-daily dosing.

A Valuable Option for Cardiovascular Treatment

This research highlights the potential of betaxolol as a valuable option for managing cardiovascular conditions. Its long duration of action and sustained efficacy suggest that it could be a convenient and effective treatment for patients requiring long-term beta-blockade.

Dr.Camel's Conclusion

Just as a camel can traverse vast distances with its reserve of energy, betaxolol offers a sustained effect on exercise tachycardia. This research provides valuable insights into the efficacy and pharmacokinetics of betaxolol, highlighting its potential as a long-acting beta-adrenoceptor antagonist. It's a reminder that the field of medicine is constantly evolving, and new discoveries are always emerging to help us better understand and treat complex diseases.

Date :
  1. Date Completed 1981-06-13
  2. Date Revised 2019-05-11
Further Info :

Pubmed ID

6111331

DOI: Digital Object Identifier

10.1111/j.1365-2125.1981.tb01121.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.